Hall Steven Edward

CIK 00016027326 companiesCAMBRIDGE, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001602732

Recent Transactions

26 trades

Award
Kymera Therapeutics, Inc.$KYMR
Stock Option (Right to Buy)
2021-06-16+20,063→ 20,063 total
Conversion
Kymera Therapeutics, Inc.$KYMR
Series A Convertible Preferred Stock
2020-08-25−2,511,198→ 0 total
Conversion
Kymera Therapeutics, Inc.$KYMR
Common Stock
2020-08-25+2,192,249→ 2,192,249 total
Conversion
Kymera Therapeutics, Inc.$KYMR
Series B Convertible Preferred Stock
2020-08-25−985,220→ 0 total
Award
Kymera Therapeutics, Inc.$KYMR
Stock Option (Right to Buy)
2020-08-20+40,127→ 40,127 total
Conversion
Forma Therapeutics Holdings, Inc.
Series B Preferred Stock
2020-06-23−5,833,333→ 0 total
Conversion
Forma Therapeutics Holdings, Inc.
Common Stock
2020-06-23+2,106,828→ 2,404,069 total
Conversion
Forma Therapeutics Holdings, Inc.
Series C Preferred Stock
2020-06-23−3,178,630→ 0 total
Award
Forma Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
2020-06-18+17,533→ 0 total
Conversion
Surface Oncology, Inc.
Common Stock
2018-04-23+3,181,817→ 3,181,817 total
Purchase
Surface Oncology, Inc.
Common Stock
2018-04-23$15.00/sh+266,000→ 3,447,817 total
Conversion
Surface Oncology, Inc.
Series A Preferred Stock
2018-04-23−7,000,000→ 0 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series E-2 Preferred Stock
2017-07-05−1,907,373→ 0 total
Conversion
Rein Therapeutics, Inc.$RNTX
Common Stock
2017-07-05+844,987→ 844,987 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series F Preferred Stock
2017-07-05−1,443,972→ 0 total
Purchase
Rein Therapeutics, Inc.$RNTX
Common Stock
2017-07-05$15.00/sh+250,000→ 1,094,987 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series E-3 Preferred Stock
2017-07-05−1,654,411→ 0 total
Conversion
Rein Therapeutics, Inc.$RNTX
Series D Preferred Stock
2017-07-05−3,390,885→ 0 total
Purchase
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16$12.00/sh+583,333→ 2,099,482 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16+630,541→ 837,437 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Series C Preferred Stock
2016-08-16−9,841,333→ 0 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16+678,712→ 1,516,149 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2016-08-16+206,896→ 206,896 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Series A Preferred Stock
2016-08-16−3,000,000→ 0 total
Conversion
Protagonist Therapeutics, Inc$PTGX
Series B Preferred Stock
2016-08-16−9,142,857→ 0 total
Award
Dare Bioscience, Inc.$DARE
Stock Option (Right to Buy)
2015-06-26+11,000→ 11,000 total

Companies

Recent Filings

Address

C/O CERULEAN PHARMA INC. 840 MEMORIAL DRIVE

CAMBRIDGE, MA, 02139

View on SEC.gov